利福平耐药结核病患者贝达喹啉耐药的流行病学、遗传特征及临床结局评估:横断面与纵向研究
该研究利用南非2015–2019年监测数据,分析利福平耐药结核病患者贝达喹啉耐药的流行病学、遗传基础及治疗结局。基线耐药率为3.8%(76/2023,95%CI 2.9–4.6),与既往贝达喹啉或氯法齐明暴露(OR 7.1,95%CI 2.3–21.9)及耐药类型相关;基线耐药者治疗成功几率较低(OR 0.5,95%CI 0.3–1)。治疗期间2.3%(16/695)发生耐药,中位90天。
要点
- 基线贝达喹啉耐药率为3.8%(76/2023,95%CI 2.9–4.6)
- 既往贝达喹啉或氯法齐明暴露者耐药风险升高(OR 7.1,95%CI 2.3–21.9)
- 基线耐药者治疗成功几率较低(OR 0.5,95%CI 0.3–1)
核心结论
- 贝达喹啉耐药与较差的治疗结局相关。
- 应优先在基线或治疗2个月后仍培养阳性时快速评估贝达喹啉耐药,尤其是既往暴露于贝达喹啉或氯法齐明的患者。
- 通过使用新型联合疗法、优化当前治疗和患者支持来预防耐药至关重要。
研究设计与样本
- 横断面与纵向分析,使用南非2015–2019年数据。
- 横断面分析纳入2023例患者,纵向分析纳入695例患者。
- 患者为开始含贝达喹啉方案治疗的耐药结核病患者,年龄≥12岁,基线培养阳性或30天内样本可用于贝达喹啉药敏试验。
- 纵向研究要求首个监测样本对贝达喹啉表型敏感。
- 对贝达喹啉耐药分离株及部分敏感分离株进行全基因组测序。
主要发现
- 2015年1月1日至2019年7月31日,8041例患者提交监测样本,2023例纳入横断面分析,695例纳入纵向分析。
- 基线贝达喹啉耐药率为3.8%(76/2023,95%CI 2.9–4.6)。
- 基线耐药与既往贝达喹啉或氯法齐明暴露相关(OR 7.1,95%CI 2.3–21.9)。
- 基线耐药与利福平耐药或MDR结核合并氟喹诺酮类或注射剂耐药(pre-XDR:OR 4.2,95%CI 1.7–10.5)或两者均耐药(XDR:OR 4.8,95%CI 2.0–11.7)相关。
- Rv0678突变是表型耐药的唯一遗传基础;基线耐药可归因于既往贝达喹啉或氯法齐明暴露者4/76(5.3%),原发传播者6/76(7.9%)。
关键数值与推荐
- 基线贝达喹啉耐药率为3.8%(76/2023,95%CI 2.9–4.6)。
- 既往贝达喹啉或氯法齐明暴露与耐药相关(OR 7.1,95%CI 2.3–21.9)。
- pre-XDR结核与耐药相关(OR 4.2,95%CI 1.7–10.5),XDR结核与耐药相关(OR 4.8,95%CI 2.0–11.7)。
- 基线耐药者治疗成功几率较低(OR 0.5,95%CI 0.3–1)。
- 治疗期间耐药累积发生率为2.3%(16/695)。
临床怎么用
- 作者认为,应优先在基线或治疗2个月后仍培养阳性时快速评估贝达喹啉耐药,尤其是既往暴露于贝达喹啉或氯法齐明的患者。
- 作者认为,通过使用新型联合疗法、优化当前治疗和患者支持来预防耐药至关重要。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Bedaquiline improves outcomes of patients with rifampicin-resistant and multidrug-resistant (MDR) tuberculosis; however, emerging resistance threatens this success. We did a cross-sectional and longitudinal analysis evaluating the epidemiology, genetic basis, and treatment outcomes associated with bedaquiline resistance, using data from South Africa (2015-19). METHODS: Patients with drug-resistant tuberculosis starting bedaquiline-based treatment had surveillance samples submitted at baseline, month 2, and month 6, along with demographic information. Culture-positive baseline and post-baseline isolates had phenotypic resistance determined. Eligible patients were aged 12 years or older with a positive culture sample at baseline or, if the sample was invalid or negative, a sample within 30 days of the baseline sample submitted for bedaquiline drug susceptibility testing. For the longitudinal study, the first surveillance sample had to be phenotypically susceptible to bedaquiline for inclusion. Whole-genome sequencing was done on bedaquiline-resistant isolates and a subset of bedaquiline-susceptible isolates. The National Institute for Communicable Diseases tuberculosis reference laboratory, and national tuberculosis surveillance databases were matched to the Electronic Drug-Resistant Tuberculosis Register. We assessed baseline resistance prevalence, mutations, transmission, cumulative resistance incidence, and odds ratios (ORs) associating risk factors for resistance with patient outcomes. FINDINGS: Between Jan 1, 2015, and July 31, 2019, 8041 patients had surveillance samples submitted, of whom 2023 were included in the cross-sectional analysis and 695 in the longitudinal analysis. Baseline bedaquiline resistance prevalence was 3·8% (76 of 2023 patients; 95% CI 2·9-4·6), and it was associated with previous exposure to bedaquiline or clofazimine (OR 7·1, 95% CI 2·3-21·9) and with rifampicin-resistant or MDR tuberculosis with additional resistance to either fluoroquinolones or injectable drugs (pre-extensively-drug resistant [XDR] tuberculosis: 4·2, 1·7-10·5) or to both (XDR tuberculosis: 4·8, 2·0-11·7). Rv0678 mutations were the sole genetic basis of phenotypic resistance. Baseline resistance could be attributed to previous bedaquiline or clofazimine exposure in four (5·3%) of 76 patients and to primary transmission in six (7·9%). Odds of successful treatment outcomes were lower in patients with baseline bedaquiline resistance (0·5, 0·3-1). Resistance during treatment developed in 16 (2·3%) of 695 patients, at a median of 90 days (IQR 62-195), with 12 of these 16 having pre-XDR or XDR. INTERPRETATION: Bedaquiline resistance was associated with poorer treatment outcomes. Rapid assessment of bedaquiline resistance, especially when patients were previously exposed to bedaquiline or clofazimine, should be prioritised at baseline or if patients remain culture-positive after 2 months of treatment. Preventing resistance by use of novel combination therapies, current treatment optimisation, and patient support is essential. FUNDING: National Institute for Communicable Diseases of South Africa.
引用
- Ismail NA, Omar SV, Moultrie H, et al. Assessment of epidemiological and genetic characteristics and clinical outcomes of resistance to bedaquiline in patients treated for rifampicin-resistant tuberculosis: a cross-sectional and longitudinal study. Lancet Infect Dis. 2021. PMID: 34780706. doi:10.1016/S1473-3099(21)00470-9
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。